Courses

Knowledge gained through this course will enhance learners’ understanding of cancer biology, the mechanism of action of systemic cancer treatments, and the use of biomarkers to select the best treatments for each patient and as a result empower staff to feel confident when communicating with patients and their families, and with clinical and non-clinical colleagues.

This course describes how bowel cancer comes about, and explains the reasons why some patients might be given treatments such as EGFR-targeted antibodies (cetuximab and panitumumab), angiogenesis inhibitors (bevacizumab and regorafenib), or immune checkpoint inhibitors (pembrolizumab) as part of their treatment.

This course provides an overview of the targeted therapies and immunotherapies given to some people with oesophageal, stomach, pancreatic or liver cancer, or cancers of the biliary system